Vutrisiran: A Game-Changer in TTR Amyloidosis Therapy

Transthyretin (TTR) amyloidosis represents a significant challenge to modern medicine, characterized by the progressive accumulation of misfolded proteins that affect multiple organ systems.Here, we present a review of the advent of vutrisiran as a breakthrough therapeutic choice that focuses on its mechanism of action, clinical efficacy, safety profile, and position in the present therapeutic paradigm.In recent clinical trials, vutrisiran has been causally linked to the potential modulation of disease progression via its innovative RNA interference mechanism, thereby providing renewed hope for patients with hereditary and wild-type TTR amyloidosis.